Mirum Pharmaceuticals (MIRM) Study result summary
Event summary combining transcript, slides, and related documents.
Study result summary
28 Sep, 2026Disease background and unmet need
Chronic hepatitis delta virus (HDV) is the most severe form of viral hepatitis, requiring hepatitis B coinfection for replication and spread.
HDV leads to rapid progression to cirrhosis and liver failure, with over 50% liver-related death in 10 years and a threefold increased risk of liver cancer compared to HBV alone.
Estimated prevalence is about 40,000 in the US, 230,000 in the US/EU, and over 12 million worldwide.
Study design and patient population
AZURE-1 is a global Phase 2b/3 study enrolling about 200 patients with chronic HDV, randomized 2:2:1 to brelovitug 300 mg weekly, 900 mg every four weeks, or delayed treatment.
The study included a broad patient population, including those with advanced liver disease, cirrhosis (41%), and portal hypertension (20%).
No upper limit on ALT for participation; 18% had ALT >5x upper limit of normal.
Brelovitug is a fully human anti-HBsAg monoclonal antibody administered subcutaneously weekly or monthly.
Efficacy results
At week 24, 56% (300 mg weekly) and 45% (900 mg monthly) achieved the combined endpoint of virologic response plus ALT normalization, versus 0% in delayed treatment (p<0.0001).
Virologic response rates were 86% (300 mg weekly) and 85% (900 mg monthly), with ALT normalization in 63% and 54% respectively at week 24.
In the Phase 2b cohort, primary endpoint rates increased to 55% for both dosing arms at week 48, with deepening viral suppression and higher ALT normalization.
No difference in response between cirrhotic and non-cirrhotic patients; all showed improvement over time.
Latest events from Mirum Pharmaceuticals
- Four approved medicines, with 2027 catalysts in HDV, PSC and PBC.MIRM
Stifel 2026 Healthcare Conference 2026 - Five 2027 filings, expanding rare-disease launches and a return to positive cash flow.MIRM
8th Annual Wolfe Research Healthcare Conference - Four approved medicines anchor growth as late-stage rare-disease programs advance.MIRM
Corporate presentation - Brelovitug met its Week 24 primary endpoint at both doses in chronic hepatitis D.MIRM
Conference presentation - A growing rare-disease portfolio pairs $715M–$720M 2026 sales guidance with key 2027 milestones.MIRM
Corporate presentation - Sales growth lifted FY26 guidance as launches and late-stage programs advanced.MIRM
Q3 2026 - 2025 sales reached $521.3M as positive late-stage results set up 2027 filings.MIRM
Corporate presentation - EXPAND met its primary endpoint, supporting a planned U.S. filing in H1 2027.MIRM
Study result - Rare disease portfolio delivers strong growth, late-stage pipeline, and robust clinical momentum.MIRM
Corporate presentation